Nomestrol

Quick links to important sections

Nomestrol

Method of action: Endocrine Therapy

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nomestrol

Quick Facts

Property Description
Active ingredient Nomegestrol Acetate, Estradiol
Form Oral tablet (Film-coated)
Pharmacological class Combined Oral Contraceptive (COC)
General purpose Prevention of pregnancy (Contraception)
Origin Synthetic progestogen and natural estrogen

What Type of Medicine is Nomegestrol Acetate/Estradiol?

Nomegestrol Acetate/Estradiol is classified as a Combined Oral Contraceptive (COC), representing a fixed-dose combination product designed for oral administration. This medicine is an oral tablet that falls under the high-level pharmacological class of sex hormones and modulators of the genital system. Its use is clinically recognized for providing effective contraception. This medication is primarily positioned for women seeking a reliable, daily oral method of preventing pregnancy.

Composition: A Combination of Synthetic Progestogen and Natural Estrogen

The medicine's composition is defined by its two International Nonproprietary Name (INN) active ingredients: Nomegestrol Acetate and Estradiol. Nomegestrol Acetate serves as a potent, synthetic progestogen derived from 19-norprogesterone. A distinctive feature of this formulation is the use of Estradiol (17beta-estradiol), which is chemically identical to the natural estrogen produced by the body, setting it apart from older formulations containing synthetic estrogens. The progestogen in this drug demonstrates high affinity for the progesterone receptor, confirming its strong binding capability.

How the Combination Achieves its General Purpose

The general therapeutic purpose of Nomegestrol Acetate/Estradiol is to provide reliable birth control by modulating the endocrine system. The active components exert powerful anti-gonadotropic activity, achieving their purpose through two primary actions: the robust suppression of the signals that trigger ovulation (preventing the release of an egg), and the subsequent alteration of the cervical mucus and uterine lining. This dual-action mechanism ensures the environment is consistently unfavorable for conception, a crucial feature for a medication designed for daily, long-term use.

Regulatory References

  1. MedlinePlus: Birth control pills overview

What side effects are possible with Nomestrol?

Possible Side Effects and Safety Information

The safety profile of Nomegestrol Acetate/Estradiol, as documented in official regulatory sources, defines potential adverse reactions by frequency and affected body system. These classifications provide a structured measure of expected effects during clinical use.

Frequency-Classified Adverse Reactions

The medicine's regulatory data classifies effects into several tiers based on reported incidence:

  • Very Common (more than 1 in 10 users): Reports include acne and changes in bleeding patterns, such as the absence of menstruation (amenorrhoea) or otherwise abnormal withdrawal bleeding.
  • Common (1 in 10 to 1 in 100 users): Effects spanning multiple systems, including headache, nausea, mood altered (e.g., depressed mood), decreased libido, and increased weight.

Serious Adverse Reactions and Safety Restrictions

Official labeling addresses rare but clinically significant risks associated with combined oral contraceptives, which are considered the highest-tier safety concerns:

  • Serious Rare Events: The risk profile includes rare occurrences of Venous Thromboembolism (VTE) and Arterial Thromboembolism (ATE), such as stroke. These risks are documented as possibilities, reflecting the established systemic effects of the pharmacological class.
  • Safety Restrictions: The medicine is contraindicated in individuals with a history of or current thromboembolic events, severe hepatic (liver) disease, or known sex hormone-dependent malignancies. These restrictions establish the absolute safety limitations for its use.

Duration-Related Patterns

The incidence of certain effects can change over time. Irregular bleeding or spotting is reported to be more frequent during the initial cycles of treatment and generally tends to decrease thereafter. Conversely, the occurrence of amenorrhoea may show a progressive increase over the first year of continuous use.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Nomegestrol Acetate/Estradiol indicates that acute overdose is associated with a low toxicity profile. Regulatory data, derived from clinical trials, confirm there have been no reports of serious adverse effects resulting from over-ingestion of the combined product, even when doses significantly exceeding the recommended amount were administered.

Documented Clinical Manifestations

Overdose manifestations are generally mild and limited to common effects associated with combined hormonal contraceptives. The documented clinical signs include nausea and vomiting. Furthermore, an observation noted in official prescribing information is the potential for slight vaginal bleeding (withdrawal bleeding) to occur in young girls following acute overdose.

Required Emergency Actions

Regulatory documents state that no specific antidote is known for Nomegestrol Acetate/Estradiol overdose. Treatment is therefore confined to symptomatic and supportive measures. Due to the absence of a known specific counteragent, medical advice must be sought immediately following any suspected over-ingestion. This ensures proper clinical evaluation and the initiation of appropriate supportive treatment to manage the limited, documented manifestations.

Therapeutic Uses of Nomestrol

What Nomestrol Treats: Main Uses and Benefits

Nomestrol (nomegestrol acetate) is a synthetic progestogen, considered relevant across domains where additional symptomatic support is needed, primarily within women's health. Its use is applied in settings marked by temporary physiological imbalance. The combination with estradiol may be part of symptomatic management applied for oral contraception. This application provides support that helps ease the overall symptom burden and is applied across domains where functional stability becomes affected. The drug is considered relevant for easing symptom clusters related to physical discomfort in conditions such as oral contraception, menstrual disturbances, and functional uterine bleeding issues.

As a monotherapy, this treatment may also assist with managing certain gynecological conditions characterized by periods of heightened symptoms. The therapy may play a role in managing symptoms related to physical discomfort. It is commonly used to help with symptoms that create noticeable physiological strain, helping patients cope more steadily with symptom fluctuations. It is relevant in contexts involving heightened systemic burden where short-term symptomatic assistance is needed.

Quick Fact: May assist with Menstrual Disturbances

Eligibility and Restrictions for Use

Nomestrol, a medication containing nomegestrol acetate, is prescribed for certain gynecological conditions. It is important for patients to consult a healthcare professional to determine if this treatment is appropriate, as its use is restricted for certain individuals and pre-existing medical conditions.


Who Can and Cannot Use Nomestrol

Patient Group Status Key Considerations
Most Patients Consult your doctor Prescribed based on individual needs and health history.
Pregnant women Should not use The drug is contraindicated during pregnancy.
Breastfeeding women Consult your doctor Use may be advised against; progestins can be excreted in breast milk.
Individuals with active or history of severe medical conditions Should not use Includes but is not limited to:
* Active venous thromboembolism (blood clots)
* Active or history of severe liver disease or tumors
* Known or suspected sex hormone-sensitive cancers (e.g., breast or genital cancers)
* Unexplained abnormal vaginal bleeding
Individuals with history of Meningioma Should not use Studies have shown an association between nomegestrol acetate and an increased risk of this generally benign brain tumor.

Your doctor will review your complete medical history, including any prior use of progestins, before prescribing Nomestrol. It is crucial to disclose all relevant health information.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Nomestrol (Nomegestrol Acetate/Estradiol) has officially documented interaction patterns that primarily affect its contraceptive efficacy and require specific regulatory constraints for co-administration.

Formally Restricted Combinations

Co-administration with certain Hepatitis C combination regimens (specifically Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir, and Glecaprevir/Pibrentasvir) is classified as either a contraindication or a restriction due to the risk of significant adverse effects or the requirement for mandatory product information amendment.

Pharmacokinetic Interactions

Category Interacting Agents Official Outcome
Enzyme Induction (Reduced Efficacy) Hepatic enzyme inducers such as Carbamazepine, Phenytoin, Rifampicin, and the herbal product St John’s Wort Causes a decrease in the serum concentrations of the active ingredients, which can reduce the contraceptive effect.
Enzyme Inhibition (Increased Exposure) Strong CYP3A4 inhibitors (e.g., certain macrolide antibiotics) May lead to an increase in the plasma concentrations of the hormonal components.

Interaction-Related Constraints

Official regulatory information requires that a barrier contraceptive method must be used during and for a period after taking enzyme-inducing medicines. Additionally, the medicine has been documented to potentially exacerbate the symptoms of hereditary and acquired angioedema (a pharmacodynamic effect). Alcohol is not expected to interact with Nomegestrol Acetate/Estradiol.

Mechanism of Action

Nomestrol, specifically Nomegestrol acetate (NOMAC), functions as a highly selective progestogen. Its primary biological target is the progesterone receptor (PR), where it acts as a potent full agonist with a high affinity comparable to or exceeding that of endogenous progesterone.

Following administration, the molecule is distributed to progesterone-responsive tissues. Upon binding to the intracellular PR, Nomestrol induces a conformational change in the receptor. This activation facilitates receptor dimerization and translocation to the cell nucleus. Within the nucleus, the activated receptor complex binds directly to specific Progesterone Response Elements (PREs) located on the DNA promoter regions of target genes. This molecular interaction modulates the transcription of specific genes, leading to an alteration in the synthesis rate of corresponding mRNAs and ultimately affecting cellular protein profiles.

In the pituitary gland, this signaling cascade results in the inhibition of gonadotropin secretion, specifically suppressing the pulsatile release of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH). This system-level physiological consequence includes the profound suppression of the normal ovarian follicular development and ovulation cycle.

Dosage and Administration Information

Official Instructions for Use

Nomestrol (nomegestrol acetate/estradiol) is an oral, film-coated tablet that must be taken according to a strict daily schedule.

Administration Scope

Parameter Instruction
Route of Administration Oral (swallowed)
Dosing Schedule One tablet daily for 28 consecutive days. Each pack contains 24 white active tablets and 4 yellow placebo tablets (the 24/4 regimen).
Timing and Frequency Tablets must be taken at about the same time every day and are taken without regard to meals.

Procedural Structure

The full course of treatment requires the continuous, daily intake of tablets from a blister pack, which dictates the order of administration:

  1. Start: Begin by taking the first white active tablet on Day 1 of the menstrual cycle (the first day of bleeding), or by following specific instructions when switching from another hormonal method.
  2. Sequence: Take the 24 white active tablets in sequence, followed by the 4 yellow placebo tablets in the designated order.
  3. Continuation: A subsequent pack must be started immediately after the last tablet of the previous pack, without any break in daily tablet intake, regardless of whether withdrawal bleeding has occurred.

Missed Dose Guidelines

Management of a missed dose is time-sensitive. If an active tablet is missed by less than 12 hours, it should be taken immediately, and subsequent tablets taken at the usual time. If missed by more than 12 hours, contraceptive protection may be reduced, and specific instructions must be followed based on the week of the cycle. Additionally, severe gastrointestinal disturbance, such as vomiting within 3 to 4 hours of taking an active tablet, requires procedural steps similar to those for a missed dose.

Recent Clinical Evidence

Nomestrol: Recent Clinical Evidence

Research on Treatment Efficacy

Studies have evaluated the drug's role in the treatment of a specific condition, typically in combination with 17beta-estradiol (E2). Research has explored whether the drug is associated with changes in the duration or severity of symptoms as measured by specific clinical scales. Findings were mixed across some sub-populations, and it is not yet clear whether a predictable therapeutic change is observed in all individuals.


Focus of Research

Research has explored the drug's activity in modulating inflammatory responses. The research reviewed primarily focused on the drug's effects in human clinical trials, particularly evaluating ovulation inhibition and cycle control.


Comparative Studies

Comparative studies have examined the outcomes of this drug against the current standard of care (often a combination of drospirenone and ethinylestradiol). These studies typically involved randomized, controlled trials. Data analysis involved measuring the percentage of participants who met the primary endpoint within a predetermined study period, with the Pearl Index frequently used as a primary endpoint.

  • Monotherapy Trials: Studies examined the drug's effect on acute episode frequency. One large trial reported a statistically observed difference in the primary efficacy endpoint compared to placebo, while another trial focused on a different patient group reported non-significant findings.
  • Combination Therapy: Research has examined whether the combination is associated with changes in patient-reported quality of life compared to monotherapy or other treatments. The findings for the combined approach indicated potential changes in specific secondary endpoints, but a clear causal relationship has not been established.

Dosage and Study Profile

The drug has been the subject of research in the context of treating specific chronic diseases.

  • Dosage: In the studies reviewed, the combination drug was typically administered once daily with a regimen of 24 active tablets (containing 2.5 mg Nomestrol and 1.5 mg E2) followed by 4 placebo days. The dose was sometimes titrated based on protocol criteria.
  • Long-term Study: Studies examined the drug's tolerability over a long-term duration in adult participants, including its influence on metabolic parameters. Research has also explored whether the drug influenced liver function parameters during extended exposure.

Key Studies & References Nomegestrol acetate: pharmacology, safety profile and therapeutic efficacy

Frequently Asked Questions (FAQ)

Common questions about Nomestrol (FAQ)

Q: How quickly does Nomestrol start to work after I take it?

A: Nomestrol is a hormonal medicine that works by suppressing ovulation. Official guidance recommends the use of a barrier method until seven days of uninterrupted active tablet-taking has been completed to establish contraceptive protection.

Q: How long do the effects of Nomestrol usually last?

A: This medication is designed for continuous daily intake to maintain its protective effect. Official product information indicates the maintenance of effectiveness is dependent on consistent, timely administration. Protection may be reduced if an active tablet is missed by more than 12 hours.

Q: Are the side effects of Nomestrol temporary?

A: The incidence of some effects can change over time. Official product data states that irregular bleeding or spotting is more frequent during the initial cycles of treatment and tends to decrease thereafter. Other documented side effects may vary in duration for each individual.

Q: Can Nomestrol be cut in half if the pill is too big?

A: Regulatory documents describe the tablets as oral, film-coated tablets. The product information does not state that the tablets are scored or safe to divide, meaning they are intended to be taken whole as supplied.

Q: What happens if I forget to take a dose of Nomestrol?

A: Management of a missed dose is time-sensitive. If an active tablet is missed by less than 12 hours, it is indicated in the guidelines that the missed dose be taken immediately. If missed by more than 12 hours, contraceptive protection may be reduced, and specific instructions must be followed based on where you are in the cycle.

Q: What have clinical studies generally shown about Nomestrol?

A: Clinical trials have evaluated the drug's effectiveness in preventing pregnancy. Studies have reported a Pearl Index (a measure of efficacy) that indicates a low rate of pregnancy during typical use. The documented safety profile includes common adverse events such as changes in bleeding patterns, acne, and weight gain.

Q: Is the evidence for Nomestrol considered strong?

A: The drug is classified as a Combined Oral Contraceptive (COC). This classification and its use are facts supported by extensive systematic reviews published in medical literature. The clinical evidence examined the drug's activity in women seeking a reliable, daily oral method of preventing pregnancy.

Q: Why do official documents mention specific populations regarding Nomestrol?

A: Restrictions and contraindications (reasons the drug should not be used) exist for certain populations, such as those with a history of blood clots or severe liver disease. This is due to the established systemic risks associated with the pharmacological class, which are detailed in official safety documents.

Q: How is Nomestrol processed by the body's liver or kidneys?

A: Nomegestrol acetate, one of the active ingredients, is primarily processed and cleared by the liver (hepatic clearance). Official product information indicates that elimination is considered unlikely to be affected by impaired kidney function.

Q: Is Nomestrol the same kind of drug as similar medicines I've heard of?

A: Nomestrol is classified as a Combined Oral Contraceptive (COC). A distinctive feature of this formulation is the use of estradiol, which is chemically identical to the natural estrogen produced by the body, setting it apart from some older COCs that use synthetic estrogens.

Q: Does taking Nomestrol with food change how it works?

A: Regulatory documents state that the tablets must be taken every day without regard to meals. This means the medication can be taken with or without food.

Q: Does Nomestrol interact with common over-the-counter pain relievers?

A: Regulatory documents list interactions with specific drug classes. However, official regulatory documents do not list common over-the-counter pain relievers, such as ibuprofen or acetaminophen, as specific interacting agents that reduce contraceptive efficacy.

Q: Can Nomestrol be used during pregnancy or while breastfeeding?

A: The drug is contraindicated (officially prohibited) during pregnancy. Use during breastfeeding is generally advised against because the drug's components can be excreted in breast milk and may affect milk production.

Q: Are children or teenagers allowed to use Nomestrol?

A: Safety and efficacy have not been established in adolescents under 18 years of age. Official product information states there is no relevant use of the medicine in children and pre-menarchal adolescents.

Q: Is there a generic version of Nomestrol available?

A: Nomestrol is a brand name for a fixed-dose combination product containing Nomegestrol Acetate and Estradiol. These active ingredients are available in fixed-dose combination products under different trade names in various regions.

Q: How does the chemical structure of Nomestrol differ from similar drugs?

A: The drug's active ingredients include Nomegestrol Acetate, a synthetic progestogen derived from 19-norprogesterone, and Estradiol, which is chemically identical to the natural estrogen produced by the body.

Q: Is it possible to be allergic to Nomestrol?

A: Yes, hypersensitivity (an allergic reaction) to the active substances or any of the inactive ingredients is listed as a contraindication in official documents. This establishes the absolute safety limitation for its use.

Q: Are there different strengths of Nomestrol tablets available?

A: The active tablets contain a fixed dose of Nomegestrol Acetate and Estradiol. Regulatory documents do not list other strengths of this specific combination.

Q: Do studies suggest any long-term health risks from taking Nomestrol?

A: The official safety profile notes rare but serious events such as Venous Thromboembolism (VTE) and Arterial Thromboembolism (ATE). These are established systemic risks for the entire pharmacological class of combined oral contraceptives.

Q: Is it normal to not feel any different right away after starting Nomestrol?

A: The drug's primary action is to suppress ovulation, which is a physiological change that is not felt immediately. It requires a continuous, daily intake to establish and maintain its contraceptive effect.

Q: Can Nomestrol affect the results of blood tests?

A: Combined oral contraceptives can affect certain laboratory test results. This may include parameters related to liver, thyroid, adrenal, and renal function, as well as protein and lipid levels.

Q: If I switch to Nomestrol from another drug, what should I expect?

A: When switching from another hormonal contraceptive, regulatory documents provide specific start instructions. These guidelines may include the temporary use of a barrier method to help ensure contraceptive protection during the transition.

Q: Is Nomestrol supposed to be taken at a specific time of day?

A: Official instructions state that tablets must be taken every day at about the same time. The exact time of day, whether morning or evening, is not specified as a requirement in official documents, as long as the timing is consistent.

Q: Does Nomestrol have a risk of withdrawal symptoms if stopped suddenly?

A: Cessation of the active pills, as part of the scheduled treatment, will result in a withdrawal bleeding (period-like bleeding). This is an expected physiological event of the tablet schedule.

Q: Can other prescription drugs reduce the effectiveness of Nomestrol?

A: Yes, drugs classified as hepatic enzyme inducers (such as certain antiepileptic drugs and antibiotics) are documented to cause a decrease in the concentration of active ingredients. This interaction may reduce the contraceptive effect of Nomestrol.

Q: Is it safe to take Nomestrol with herbal supplements?

A: Official documents list the herbal product St John’s Wort as a documented interacting agent that reduces contraceptive efficacy. This highlights the need for caution with enzyme-inducing herbal products.

How should Nomestrol be stored and disposed of?

Storage Requirements

Storage Scope Official Regulatory Requirement
Temperature: Store below 30 C (or 86 F) [EMA SmPC, TGA].
Protection: Store out of direct light, moisture, and heat [TGA].
Container: Keep the medicine in the original packaging (blister and carton) [TGA].
Shelf-Life: Stability data supports a shelf life of 3 years when stored below 30 C [TGA AusPAR].
Handling Constraints: Do not store in the car, on windowsills, in the bathroom, or near a sink [TGA].

Disposal and Child Safety

  • Child Safety: The product must be kept in a safe place, away from children [TGA].
  • Disposal: The disposal of unused product and container should be handled by an approved waste disposal plant in accordance with local or national regulations [SDS]. Release to the environment should be avoided due to the formulation's composition [SDS].

The storage criteria strictly define a cool, dry environment to ensure product integrity for the stated shelf life. The disposal mandates, based on regulatory classification, require specialized pharmaceutical waste procedures rather than general household or wastewater disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nomestrol found in:

A-Z Index: